152 related articles for article (PubMed ID: 32767957)
1. Phthalazinone Scaffold: Emerging Tool in the Development of Target Based Novel Anticancer Agents.
Singh J; Suryan A; Kumar S; Sharma S
Anticancer Agents Med Chem; 2020; 20(18):2228-2245. PubMed ID: 32767957
[TBL] [Abstract][Full Text] [Related]
2. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
Prime ME; Courtney SM; Brookfield FA; Marston RW; Walker V; Warne J; Boyd AE; Kairies NA; von der Saal W; Limberg A; Georges G; Engh RA; Goller B; Rueger P; Rueth M
J Med Chem; 2011 Jan; 54(1):312-9. PubMed ID: 21128645
[TBL] [Abstract][Full Text] [Related]
3. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
[TBL] [Abstract][Full Text] [Related]
4. Phthalazin-1(2H)-one as a remarkable scaffold in drug discovery.
Vila N; Besada P; Costas T; Costas-Lago MC; Terán C
Eur J Med Chem; 2015 Jun; 97():462-82. PubMed ID: 25482553
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
[No Abstract] [Full Text] [Related]
6. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
7. New 1-phthalazinone Scaffold based Compounds: Design, Synthesis, Cytotoxicity and Protein Kinase Inhibition Activity.
Abo-Elmagd NE; George RF; Ezzat MA; Arafa RK
Mini Rev Med Chem; 2018; 18(20):1759-1774. PubMed ID: 30179133
[TBL] [Abstract][Full Text] [Related]
8. Development of novel proteasome inhibitors based on phthalazinone scaffold.
Yang L; Wang W; Sun Q; Xu F; Niu Y; Wang C; Liang L; Xu P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2801-2805. PubMed ID: 27158142
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
[TBL] [Abstract][Full Text] [Related]
10. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.
Cockcroft XL; Dillon KJ; Dixon L; Drzewiecki J; Kerrigan F; Loh VM; Martin NM; Menear KA; Smith GC
Bioorg Med Chem Lett; 2006 Feb; 16(4):1040-4. PubMed ID: 16290932
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anticancer activities of novel 1,4-disubstituted phthalazines.
Li J; Zhao YF; Yuan XY; Xu JX; Gong P
Molecules; 2006 Jul; 11(7):574-82. PubMed ID: 17971729
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors.
El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F
Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Biological Evaluation of New Phthalazinone Derivatives as Anti-Inflammatory and Anti-Proliferative Agents.
Hameed AD; Ovais S; Yaseen R; Rathore P; Samim M; Singh S; Sharma K; Akhtar M; Javed K
Arch Pharm (Weinheim); 2016 Feb; 349(2):150-9. PubMed ID: 26725221
[TBL] [Abstract][Full Text] [Related]
15. Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
Yamaguchi M; Kamei K; Koga T; Akima M; Maruyama A; Kuroki T; Ohi N
J Med Chem; 1993 Dec; 36(25):4061-8. PubMed ID: 8258828
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.
Lu X; Peng Y; Wang C; Yang J; Bao X; Dong Q; Zhao W; Tan W; Dong X
Eur J Med Chem; 2017 Sep; 138():384-395. PubMed ID: 28688278
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L
Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
Zhong Y; Meng Y; Xu X; Zhao L; Li Z; You Q; Bian J
Bioorg Chem; 2019 Oct; 91():103181. PubMed ID: 31404795
[TBL] [Abstract][Full Text] [Related]
20. Design and Synthesis of New Phthalazinone Derivatives Containing Benzyl Moiety with Anticipated Antitumor Activity.
Marzouk MI; Shaker SA; Abdel Hafiz AA; El-Baghdady KZ
Biol Pharm Bull; 2016; 39(2):239-51. PubMed ID: 26830483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
